DelveInsight Business Research LLP

Merus N.V. had a strong start this month, securing a long-awaited commercialization partner for its zenocutuzumab, which has now received FDA approval. The drug becomes the first to target cancers with a neuregulin 1 (NRG1) gene fusion. The FDA granted accelerated approval to the drug, now known as BIZENGRI, for treating NRG1 fusion-positive non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma in patients whose condition has worsened after prior systemic therapy. The approval is based on the eNRGy trial, a multicenter, open-label study involving patients with advanced, unresectable, or metastatic NRG1+ NSCLC or pancreatic adenocarcinoma who had previously experienced disease progression. The approval of BIZENGRI intensifies competition in the NRG fusion market, which is expected to grow at a CAGR of 15%, driven by the recent drug approval and a rise in NRG1 fusion biomarker testing from 2020 to 2034. Additionally, other companies like Hummingbird Bioscience (HMBD-001) and Salubris Biotherapeutics (Seribantumab) are also working on novel NRG fusion therapies. Get detailed insights on the evolving landscape of the NRG1 fusion market due to BIZENGRI approval at: https://lnkd.in/gUf-ZemM

Congratulations, Yash B., on reaching 5-year milestone with us! Your unwavering dedication to delivering excellence has been nothing short of inspiring. Your contributions have not only enhanced the fabric of our workplace but have also propelled our company's progress forward. Your infectious positivity, collaborative spirit, and relentless drive to exceed expectations have become the gold standard for our team. As we celebrate this significant moment, we want to extend our heartfelt appreciation for your tireless efforts, resilience in the face of challenges, and steadfast commitment. Your invaluable presence has undoubtedly made a profound impact, and we are genuinely grateful to have you as an integral member of our team. Looking ahead, we eagerly anticipate the continuation of our partnership with you and are excited to witness the many more achievements that lie ahead in your journey with us. Here's to many more years of success, growth, and shared accomplishments together. #fiveyears #fiveyearanniversary #workanniversary #workanniversaries #thankyou #dedication #kudos #goingaboveandbeyond #goingtheextramile #zeal  #commitment #excellence #positiveattitude #hardwork #focus #appreciation #milestoneachievement #teamsuccess #employeeappreciation

AstraZeneca has received another approval for its cancer drug IMFINZI (durvalumab), with the FDA authorizing the PD-L1 inhibitor for patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed after concurrent chemotherapy and radiation. This marks IMFINZI as the first immunotherapy treatment for LS-SCLC, a highly aggressive form of cancer with a post-diagnosis survival rate of 15% to 30%.   The approval followed a Priority Review and Breakthrough Therapy Designation from the FDA, based on results from the ADRIATIC Phase III trial, which were presented at the 2024 ASCO Annual Meeting and later published in the New England Journal of Medicine. IMFINZI has been approved for this indication in Switzerland based on the ADRIATIC trial results, and regulatory evaluations are currently in progress in the EU, Japan, and other nations. Track the complete approval journey of IMFINZI as the first and only immunotherapy for LS-SCLC at: https://lnkd.in/gtZahvMq

Med-Tech News & Trends: China's NMPA Approved Magbot Robotic Magnetic Navigation Ablation Catheter AngioDynamics Received FDA Clearance for NanoKnife® System for Prostate Tissue Ablation  Zynex Medical Announced Completion of Its Laser Pulse Oximetry Trial Study Results From COTA, PreciseDx, and BAPTIST HEALTH SOUTH FLORIDA FOUNDATION INC Validated AI Test PreciseBreast as Equivalent to Oncotype DX in Predicting Breast Cancer Recurrence  Medtronic Launched Percept™ RC Rechargeable Neurostimulator in India  Crown Aesthetics Introduced SkinPen® Precision Elite in the US, Setting a New Standard in Microneedling Get more details, at: https://lnkd.in/gYUQ-USK #lifesciences #pharmaceuticals #marketresearch #marketanalysis #healthcare #markettrends #health #medical #news #healthcarenews #medtech #medtechnews

Today, on Universal Health Coverage Day 2024, we stand united under this year’s theme: "Health: It's on the government." At DelveInsight Business Research LLP, we are committed to fostering innovation, research, and strategies that contribute to universal access to quality healthcare. Achieving health coverage for everyone isn’t just a goal, it’s a necessity for building resilient communities and ensuring no one is left behind. Let’s continue to collaborate, innovate, and advocate for a future where healthcare is a right, not a privilege. Together, we can make universal health coverage a reality. How are you contributing to the mission of health for all? Share your thoughts below. #UniversalHealthCoverageDay #UHC2024 #HealthForAll #DelveInsight #GlobalHealth #EquityInHealth

Exciting Developments in Parkinson's Disease Treatment! The journey to finding effective treatments for Parkinson’s disease is advancing, with groundbreaking progress in the pipeline. This article highlights 7 of the most promising drugs currently under development, offering hope to millions affected by this complex condition. From innovative mechanisms to life-changing potential, these therapies could redefine how we address Parkinson's Disease. Prominent late-stage therapies in development include Cerevel Therapeutics/AbbVie’s tavapadon, Pharma Two B’s P2B001 (a combination of extended-release pramipexole and rasagiline), Supernus Pharmaceuticals, Inc.’ SPN-830 (apomorphine infusion pump), Mitsubishi Tanabe Pharma Corporation/ NeuroDerm, A Mitsubishi Tanabe Pharma Group Company Ltd.’s ND0612 (levodopa/carbidopa), Cerevance’s Solengepras (CVN424), UCB Biopharma S/A/Novartis’s Minzasolmin (UCB0599), and Annovis Bio, Inc. Bio’s Buntanetap/ANVS402/ANVS401, among others. Explore the full article to learn more about the future of neurodegenerative disease treatment: https://lnkd.in/gQDVKgmp What do you think about these advancements? Let’s discuss! #HealthcareInnovation #ParkinsonsDisease #Pharma #Neurology #Biotech

Biosensors are analytical devices that combine a biological component with a physicochemical detector to monitor biological or chemical reactions. These devices are widely used in medical diagnostics, environmental monitoring, food safety, and biotechnology. In medical applications, biosensors can detect glucose levels, pathogens, or other biomolecules in bodily fluids, making them critical for managing chronic diseases such as diabetes. Environmental monitoring, including detecting pollutants and toxins in air or water, is another growing application. Biosensors have also found roles in the food industry, where they are used to ensure product quality and safety by detecting contamination or spoilage. The biosensor market is expanding rapidly, driven by advancements in biotechnology, healthcare, and environmental sustainability. Key factors fueling growth include increasing demand for point-of-care diagnostics, growing awareness of preventive healthcare, and the rise of personalized medicine. Additionally, the market is benefiting from the adoption of wearable biosensors, which allow continuous monitoring of health parameters. Leading companies in the biosensor market include Abbott Laboratories - Lafrancol S.A.S, Roche, Siemens Healthineers, and Medtronic. These companies are investing heavily in research and development to introduce innovative biosensor technologies, such as multi-analyte sensors and wireless biosensors, to meet the growing demand for real-time, accurate health monitoring and environmental detection. Get a complete overview of how the biosensors are revolutionizing the healthcare industry at: https://lnkd.in/gdeZTHfT

Latest Healthcare News & Updates: AbbVie Unveils Positive Phase III TEMPO-2 Trial Findings for Tavapadon as Parkinson's Disease Monotherapy US FDA Moves Forward with GSK’s NUCALA (mepolizumab) Submission for COPD Novartis Strengthens Neuroscience Pipeline with PTC518 in-licensing for Huntington’s Disease Chimerix, Inc. Plans to Seek Accelerated FDA Approval for Dordaviprone in Recurrent H3 K27M-Mutant Diffuse Glioma Patients by Year-End FDA Grants RMAT Designation to MeiraGTx's AAV2-hAQP1 for Radiation-Induced Xerostomia Get more detailed analysis, at: https://lnkd.in/gynjkE4T #lifesciences #pharmaceuticals #marketresearch #marketanalysis #healthcare #markettrends #health #medical #news #healthcarenews #pharmanews #clinicaltrials #clinicalresearch

In the fast-evolving field of cancer treatment, CDK4/6 inhibitors are gaining attention for their transformative effects. These groundbreaking drugs are reshaping the treatment of cancers driven by uncontrolled cell division, especially hormone receptor-positive, HER2-negative breast cancers. By targeting key regulators of the cell cycle, CDK4/6 inhibitors attack the root cause of cancer's unchecked growth, providing renewed hope for both patients and healthcare providers. With strong clinical data, innovative combinations, and growing uses, CDK4/6 inhibitors are leading a new era in oncology—blending scientific advances with precision medicine for truly transformative care. Three CDK4/6 inhibitors have received FDA approval for breast cancer treatment: IBRANCE (Pfizer), VERZENIO (Eli Lilly and Company), and KISQALI (Novartis). VERZENIO is typically taken daily as a standalone pill and primarily targets CDK4. IBRANCE and KISQALI target both CDK4 and CDK6 and are used in combination with hormonal therapies. In Japan, palbociclib was approved in 2017 for unresectable or recurrent breast cancer, and abemaciclib was approved in 2018 for advanced HR+/HER2− breast cancer. There is significant potential to extend the use of CDK4/6 inhibitors beyond HR+/HER2− advanced breast cancer. Additionally, COSELA, another CDK4/6 inhibitor, has been approved for extensive-stage small-cell lung cancer. The potential for broadening the use of CDK4/6 inhibitors is promising, particularly for patients who develop resistance to combined CDK4/6 inhibitors and endocrine treatments. These patients often switch to conventional chemotherapy due to unsatisfactory results with single-agent fulvestrant. Several new CDK4/6 inhibitors are currently being explored in early-stage clinical trials for various indications, including Trilaciclib (G1 Therapeutics, Inc.), SPH4336 (Shanghai Pharma Biotherapeutics USA Inc.), Lerociclib (G1 Therapeutics, Inc. and Pepper Bio), Narazaciclib + Letrozole (Traws Pharma, Inc), PRT3645 (Prelude Therapeutics), and Euthare-155008 (Shengke Pharmaceuticals (Jiangsu) Limited). Discover how CDK4/6 inhibitors are transforming cancer treatment at: https://lnkd.in/gWhmHhvR

DelveInsight's analysis projects the global artificial sweeteners market to grow at a CAGR of ~4% by 2030, with Asia-Pacific anticipated to lead the market during the forecast period. In 2023, the stevia segment held a significant revenue share within the artificial sweeteners market, highlighting its growing popularity. Prominent companies shaping the artificial sweeteners landscape include Cargill, Nestlé, Tate & Lyle, Ingredion Incorporated, ADM, Ajinomoto Co., Inc., Hermes Sweeteners Ltd., and others, driving innovation and expanding market opportunities. Get more details here: https://lnkd.in/gAXPKpbM. #ArtificialSweeteners #GlobalMarket #Stevia #FoodInnovation #Cargill #Nestlé #TateAndLyle #ADM #Ajinomoto #HealthAndWellness #MarketTrends #Biotechnology #DelveInsight